Literature DB >> 10336428

The A1 and A2 subunits of factor VIIIa synergistically stimulate factor IXa catalytic activity.

P J Fay1, K Koshibu, M Mastri.   

Abstract

Factor VIIIa, the protein cofactor for factor IXa, is comprised of A1, A2, and A3-C1-C2 subunits. Recently, we showed that isolated A2 subunit enhanced the kcat for factor IXa-catalyzed activation of factor X by approximately 100-fold ( approximately 1 min-1), whereas isolated A1 or A3-C1-C2 subunits showed no effect on this rate (Fay, P. J., and Koshibu, K. J. (1998) J. Biol. Chem. 273, 19049-19054). However, A1 subunit increased the A2-dependent stimulation by approximately 10-fold. The Km for factor X in the presence of A2 subunit was unaffected by A1 subunit, whereas the kcat observed in the presence of saturating A1 and A2 subunits ( approximately 15 min-1) represented 5-10% of the value observed for native factor VIIIa (approximately 200 min-1). An anti-A1 subunit antibody that blocks the association of A2 eliminated the A1-dependent contribution to factor IXa activity. Inclusion of both A1 and A2 subunits resulted in greater increases in the fluorescence anisotropy of fluorescein-Phe-Phe-Arg factor IXa than that observed for A2 subunit alone and approached values obtained with factor VIIIa. These results indicate that A1 subunit alters the A2 subunit-dependent modulation of the active site of factor IXa to synergistically increase cofactor activity, yielding an overall increase in kcat of over 1000-fold compared with factor IXa alone.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10336428     DOI: 10.1074/jbc.274.22.15401

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  6 in total

1.  Effect of HLA DR epitope de-immunization of Factor VIII in vitro and in vivo.

Authors:  Leonard Moise; Chang Song; William D Martin; Ryan Tassone; Anne S De Groot; David W Scott
Journal:  Clin Immunol       Date:  2011-12-08       Impact factor: 3.969

2.  The regulation of factor IXa by supersulfated low molecular weight heparin.

Authors:  Tina M Misenheimer; John P Sheehan
Journal:  Biochemistry       Date:  2010-10-27       Impact factor: 3.162

Review 3.  Factor IX(a) inhibitors: an updated patent review (2003-present).

Authors:  Daniel K Afosah; Edward Ofori; Madhusoodanan Mottamal; Rami A Al-Horani
Journal:  Expert Opin Ther Pat       Date:  2022-01-17       Impact factor: 6.674

Review 4.  Characteristics, mechanisms of action, and epitope mapping of anti-factor VIII antibodies.

Authors:  Géraldine Lavigne-Lissalde; Chantal Rothschild; Claire Pouplard; Priscilla Lapalud; Yves Gruel; Jean-François Schved; Claude Granier
Journal:  Clin Rev Allergy Immunol       Date:  2009-10       Impact factor: 8.667

5.  Structural investigation of zymogenic and activated forms of human blood coagulation factor VIII: a computational molecular dynamics study.

Authors:  Divi Venkateswarlu
Journal:  BMC Struct Biol       Date:  2010-02-25

6.  The heparin-binding exosite of factor IXa is a critical regulator of plasma thrombin generation and venous thrombosis.

Authors:  Yang Buyue; Herbert C Whinna; John P Sheehan
Journal:  Blood       Date:  2008-07-22       Impact factor: 22.113

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.